Skip to main content

Table 4 Randomized clinical trials of HCC treatment with SA monotherapy

From: The GH-IGF-SST system in hepatocellular carcinoma: biological and molecular pathogenetic mechanisms and therapeutic targets

Publication Type of study Number of enrolled patients and controls Type of Cancer SA used for treatment Response to treatment-outcome
   Patients Controls    
Kourumalis 1998[220] RCT 28* 30# Advanced HCC OCT SC (500 μg/d) ↓AFP,↑S, ↑QoL
Yuen 2002[221] RCT 35* 35° Advanced HCC OCT LAR (30 mg/28d) None
Dimitroulopoulos 2007[166] RCT 24* (Octreoscan +) 30° (Octreoscan +) Advanced HCC OCT LAR (20 to 30 mg/28d) ↑S, ↑QoL
66# (Octreoscan -)
Becker 2007[223] RCT 60* 59° Advanced HCC OCT LAR (30 mg/28d) None
Barbare 2009[224] RCT 135* 137° Advanced HCC OCT LAR (30 mg/28d) =S, ↓QoL
  1. RCT, Randomized clinical trial.
  2. AFP, Alpha fetoprotein.
  3. S, Survival.
  4. QoL, Quality of life.
  5. *: treated patients.
  6. #: untreated patients.
  7. °: placebo controls.